TOI Stock Risk & Deep Value Analysis
Oncology Institute Inc
Healthcare • Medical Care Facilities
DVR Score
out of 10
What You Need to Know About TOI Stock
We analyzed Oncology Institute Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TOI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
TOI Risk Analysis & Red Flags
What Could Go Wrong
Despite the recent Q1 2026 beat, TOI continues to operate with significant negative cash flow from operations (estimated >$20M/quarter burn based on Q1 2026 SEC filings) and low cash reserves (approx. $25M as of Q1 2026). If the company fails to accelerate its path to positive EBITDA and cash flow generation, it will require further highly dilutive capital raises within the next 12-18 months, severely hindering any shareholder returns and potentially risking solvency.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Persistent negative Free Cash Flow (estimated >$20M/quarter burn based on Q1 2026 SEC filings) without a clear, near-term path to profitability.
- ⚠
Very high Debt-to-Equity ratio (due to negative equity) indicating an unsustainable capital structure, as per Q1 2026 10-Q.
- ⚠
Insider selling by Chief Medical Officer Yale Podnos ($126,093 on June 8, 2026) counteracting positive sentiment from the 10% owner buy.
- ⚠
Cyber incident disclosure (May 20, 2026) involving patient data, despite company's claim of no material impact, poses ongoing reputational and potential financial risk.
Upcoming Risk Events
- 📅
Q2 2026 earnings miss (estimated August 12, 2026): A significant miss on revenue or EPS consensus, or a downward revision of FY2026 guidance, could reverse recent positive momentum and trigger further investor skepticism.
- 📅
Escalation of cybersecurity incident impact (H2 2026): Legal action from affected patients, regulatory fines exceeding $10M, or significant operational disruptions linked to the May 2026 data breach, impacting financial condition and market perception.
When to Reconsider
- 🚪
Exit if quarterly revenue growth (YoY) decelerates below 10% for two consecutive quarters, signaling a loss of expansion momentum.
- 🚪
Sell if cash and cash equivalents, as reported in the 10-Q, fall below $15 million, indicating an imminent need for emergency financing.
- 🚪
Exit if net loss per share worsens (i.e., becomes more negative) for two consecutive quarters after the Q1 2026 improvement, suggesting a reversal in operational efficiency.
Unlock TOI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Oncology Institute Inc (TOI) Do?
Market Cap
$467.92M
Sector
Healthcare
Industry
Medical Care Facilities
Employees
825
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Visit Oncology Institute Inc WebsiteInvestment Thesis
If The Oncology Institute can consistently replicate its Q1 2026 operational beat, specifically by exceeding $150M in quarterly revenue and pushing EPS closer to breakeven (e.g., -$0.01 or better) by Q4 2026, then the market could re-rate its valuation from the current ~0.7x to 1.5x FY2026 revenue, implying a potential market cap of $960M ($9.60/share). This is bullish because the market is currently pricing in continued financial distress and overlooks the potential for operational leverage as the value-based care model matures.
Is TOI Stock Undervalued?
Unlock the full AI analysis for TOI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TOI Price Targets & Strategy
12-Month Target
$7.50
Bull Case
$12.00
Bear Case
$2.00
Valuation Basis
Based on 1.2x estimated FY2026 revenue of $640M (midpoint guidance) leading to an approximate $768M market cap, then dividing by ~100M shares outstanding.
Entry Strategy
Dollar-cost average between $4.00-$4.50 (near recent support levels and current trading range).
Exit Strategy
Take 50% profit at $7.00, set a stop loss at $3.50 if financial conditions deteriorate.
Portfolio Allocation
1% for aggressive risk tolerance, due to high financial and execution risks.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is TOI Financially Healthy?
Valuation
P/E Ratio
-13.22
Price/Book
-30.45
Price/Sales
0.93
Profitability
Gross Margin
15.12%
Operating Margin
-5.99%
Net Margin
-7.97%
Return on Equity
-482.58%
Revenue Growth
35.37%
EPS
$-0.45
Balance Sheet
Current Ratio
1.59
Quick Ratio
1.31
Debt/Equity
25.95
Cash & Equivalents
$30.28M
Cash Flow
Free Cash Flow
-$25.73M
EBITDA
-$25.91M
Other
Beta (Volatility)
0.36
Does TOI Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable
Moat Sources
2 Identified
Low, as their business model can be replicated by larger, better-capitalized health systems or competitors with more robust technology and patient networks, without significant barriers to entry.
Moat Erosion Risks
- •Increased competition from larger, well-funded health systems or private equity-backed groups entering or expanding value-based oncology care initiatives.
- •Inability to achieve sufficient scale or cost efficiencies to make their value-based care model sustainably profitable, thereby failing to differentiate on unit economics.
TOI Competitive Moat Analysis
Sign up to see competitive advantages
TOI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - small-cap with recent positive earnings news offset by ongoing fundamental financial challenges, leading to mixed retail investor discourse.
Institutional Sentiment
Neutral - No recent analyst upgrades or downgrades provided. Mixed insider activity with a 10% owner buying, but a CMO selling and CEO's tax-related share issuance.
Insider Activity (Form 4)
Mixed. Chernett Jorey (10% owner) bought 12,000 shares ($57,000) on June 4, 2026. Daniel Virnich (CEO) had an issuer sale to cover taxes for RSU vesting (23,058 shares, $103,000) on Form 4. Yale Podnos (CMO) sold 23,451 shares ($126,093) on June 8, 2026.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
2026-08-12 (Estimated for Q2 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Q1 2026 saw a beat on both revenue and EPS, which may set a positive expectation for subsequent reports, though historical reactions have likely been volatile given the company's financial challenges.
Key Metrics to Watch
Competitive Position
Top Competitor
OneOncology (private)
Market Share Trend
Stable to potentially gaining slightly, implied by revenue guidance and beats, but specific market share data is not available.
Valuation vs Peers
Trading at a significant discount on Price/Sales (approx. 0.7x FY26 sales) compared to healthier, publicly traded healthcare providers that may trade at 1.5x-3x sales, reflecting its ongoing financial distress and lack of profitability.
Competitive Advantages
- •Specialized focus on a value-based care model in oncology, which aligns with evolving healthcare payment trends.
- •Established network of oncology clinics and physician partnerships in its operating regions.
- •Potential for integrated care delivery and data analytics to optimize patient outcomes and cost efficiencies.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive TOI Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 earnings report (estimated August 12, 2026): If TOI consistently beats EPS consensus (e.g., better than -$0.07) and reports revenue exceeding $150M, it would demonstrate continued operational improvement and progress towards positive EBITDA.
- •New or expanded payer contract announcement (Q3 2026): A specific announcement of a new large-scale contract with a major health plan or government program (e.g., $50M+ annualized revenue) that expands their value-based care network or geographic reach.
Medium-Term (6-18 months)
- •Achievement of Adjusted EBITDA positivity (FY2027 guidance): Clear execution and reporting of positive adjusted EBITDA, signaling a crucial turning point from persistent cash burn and improving financial sustainability.
- •Full resolution of cybersecurity incident and strengthened data security (Q1 2027): A formal announcement of enhanced security infrastructure, confirming full containment and remediation, and providing assurance that no material long-term financial or reputational damage will occur from the May 2026 incident.
Long-Term (18+ months)
- •Sustainable free cash flow generation (FY2028): Consistent reporting of positive free cash flow, allowing for debt reduction and potential share repurchases, thereby validating the long-term financial viability of their value-based care model.
- •Strategic acquisitions expanding geographic footprint or specialty services (FY2028-2029): Targeted M&A that adds $100M+ in new annual revenue and leverages economies of scale within their value-based care framework.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for TOI?
- ✓
Watch quarterly Adjusted EBITDA: must demonstrate consistent reduction in losses, moving towards positivity within 12 months.
- ✓
Watch cash and cash equivalents reported in the 10-Q: must demonstrate stability or growth (e.g., consistently above $30M) to allay liquidity concerns.
- ✓
Watch for new contract announcements and patient enrollment trends: sustained acceleration in these metrics would indicate successful scaling of their value-based model.
Bull Case Analysis
Sign up free to see the bull case
Competing with TOI
See how Oncology Institute Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Oncology Institute Inc TOI | $467.9M | 2.9 | -13.2 | $545.8M | -8.0% | 35.4% | |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Oncology Institute Inc Makes Money
The Oncology Institute, Inc. (TOI) operates a network of oncology clinics across several states, focusing on a value-based care model for cancer treatment. This means they aim to deliver high-quality, comprehensive cancer care to patients while also managing costs effectively through coordinated care and integrated services. Their objective is to improve patient outcomes and overall healthcare efficiency by shifting away from traditional fee-for-service models. The company primarily generates revenue through contracts with health plans and other payers who entrust TOI with managing the care of their oncology patient populations.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Oncology Institute Inc (TOI)?
As of June 11, 2026, Oncology Institute Inc has a DVR Score of 2.9 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Oncology Institute Inc?
Oncology Institute Inc's market capitalization is approximately $467.9M. The company operates in the Healthcare sector within the Medical Care Facilities industry.
What ticker symbol does Oncology Institute Inc use?
TOI is the ticker symbol for Oncology Institute Inc. The company trades on the NCM.
What is the risk level for TOI stock?
Our analysis rates Oncology Institute Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TOI?
Oncology Institute Inc currently has a price-to-earnings (P/E) ratio of -13.2. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Oncology Institute Inc's revenue growing?
Oncology Institute Inc has reported revenue growth of 35.4%. The company is showing strong top-line momentum.
Is TOI stock profitable?
Oncology Institute Inc has a profit margin of -8.0%. The company is currently unprofitable.
How often is the TOI DVR analysis updated?
Our AI-powered analysis of Oncology Institute Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TOI (Oncology Institute Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.